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Background. The immunosuppressant mycophenolic acid
(MMF) has been used successfully to manage proliferative
forms of systemic lupus erythematosus (SLE) glomerulonephri-
tis (GN) World Health Organization (WHO) Classes III and IV.
Less is known about MMF treatment of membranous SLE GN
(WHO Class V, SLE MN).
Methods. We report our experience with MMF therapy in
13 consecutive SLE MN patients participating in a prospective
study of risk factors for SLE flare.
Results. Baseline characteristics were: mean age 33 ± 14 SD
years, female/male ratio 11/2, Caucasians 7, African Americans
5, Oriental 1, serum creatinine 1.02 ± 0.41, and mean 24-hour
urine protein (P)/creatinine (C), ratio 5.1 ± 4.1. Initial therapy
was prednisone mean dose 31 ± 17 mg/day, and MMF mean
dose 1173 ± 746 mg/day. Therapy also featured interventions to
achieve renoprotection and proteinuria reduction. At 6 months
of therapy, complete or partial remission was achieved in 10
of 13 patients. At most recent follow-up visit (mean follow-up
16 ± 8 months), 9 of 13 patients were in complete remission, and
in 11 of 13 patients, urine P/C ratio was <0.8. During follow-up,
serum creatinine either stabilized or was improved. The only
serious complication during 208 patient months of follow-up
was histoplasma pneumonia in 1 patient.
Conclusion. These promising results suggest that moderate
dose MMF in combination with renoprotective/antiproteinuria
therapy warrants further study in the management of SLE MN.
The role of mycophenolic acid (MMF) as an effective
immunosuppressant was established in randomized clini-
cal trials comparing MMF to azathioprine to prevent kid-
ney transplant rejection [1–3]. There is a growing body
of evidence that MMF is also effective in systemic lu-
pus erythematosus glomerulonephritis (SLE GN). How-
ever, almost all of those studies treated proliferative
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forms of SLE GN [4–7] [abstract; Ginzler, Arth Rheum
48(Suppl):S647, 2003]. The largest previously reported
experience involving MMF therapy in SLE MN is the 10
patients in the Ginzler study who completed the 6 months
of protocol MMF therapy [abstract; Ginzler, Arth Rheum
48(Suppl):S647]. Our work complements that of Ginzler,
who studied the effects of higher dose MMF (3000 mg/
day). We studied lower dose MMF (mean about
1200 mg/day) with emphasis on concurrent renoprotec-
tive/antiproteinuric therapies.
It is generally agreed that SLE MN is less aggressive
than the proliferative forms of SLE GN, but there is not
general agreement regarding its management. Some rec-
ommend no therapy of SLE MN except for that needed
to control nonrenal SLE manifestations [8–10]. The ratio-
nale is that SLE MN is generally indolent and can undergo
spontaneous remission, similar to that of idiopathic mem-
branous nephropathy (MN) [11, 12]. Arguing against
nontreatment of SLE MN are the long-term follow-up
studies showing that by 7 to 10 years of sustained pro-
teinuria, about 25% of SLE MN patients progress to end-
stage renal disease (ESRD) [13, 14]. The mechanisms of
SLE MN progression to ESRD may involve the nephro-
toxicity of proteinuria [15, 16], or transformation to a
proliferative form of SLE GN [17]. A further risk of un-
treated SLE MN is that chronic heavy proteinuria leads
to hyperlipidemia and atherosclerosis, and to a hyperco-
agulable state and thromboses [16].
Currently, most authors favor treatment of SLE MN
[13, 17–19]. Glucocorticoids (steroids) were the drugs first
used to treat SLE MN [9, 11, 19, 20]. However, only about
35% of these steroid-treated SLE MN patients experi-
enced remission [12, 17–19] [abstract; Radhakrishnan J
et al, J Am Soc Nephrol 4:284], a frequency similar to
that observed in untreated idiopathic MN [21]. This sug-
gests that steroid therapy is of limited effectiveness in
inducing and sustaining remission of proteinuria in SLE
MN.
Better results in the therapy of SLE MN have been
obtained by combining steroids with immunosuppres-
sive drugs, such as alkylating agents, azathioprine, or
cyclosporine [13, 14, 18]. MMF may have advantages
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over these drugs with regard to safety and efficacy.
Specifically, MMF has a better side effects profile than
alkylating agents, better immunosuppressive effects than
azathioprine without increasing the toxicity, and is free of
the nephrotoxicity associated with cyclosporine therapy.
Indeed, the results of our study, although uncontrolled,
suggest that moderate-dose MMF therapy when com-
bined with steroids and antiproteinuria/renoprotective
therapies is safe and effective in inducing and sustaining
remission of proteinuria in SLE MN.
METHODS
The study patients are the first 13 patients with biopsy-
proven SLE MN [22] enrolled in the Ohio SLE Study
(OSS), which is the clinical component of the National
Institutes of Health Program Project titled “Genetic and
Clinical Risk Factors for Human SLE nephritis.” The OSS
is a prospective longitudinal study of SLE patients with
4 or more American College of Rheumatology criteria
for SLE [23] and recurrently active SLE (2 or more SLE
relapses requiring an increase in therapy in the previ-
ous 3 years) or persistently active disease (≥4 months
of active SLE despite therapy consisting of at least ≥20
mg prednisone daily). The goal of the OSS is to identify
risk factors for SLE flare. None had received ACE in-
hibitor (ACEI), angiotensin receptor blocker (ARB), or
immunosuppressive therapy prior to the onset of their
nephropathy.
MMF was begun usually at 500 mg twice daily and then
increased to 750 or 1000 mg twice daily by 2 to 4 weeks, if
tolerated. These doses were patterned after our original
report of MMF use in SLE nephritis [4]. The prednisone
dose was chosen to control extrarenal SLE manifesta-
tions. Renoprotective/antiproteinuria therapies used are
those previously described [15, 16]. In brief, the blood
pressure goal was a sitting systolic blood pressure in the
120 mm Hg or less, if tolerated. All patients received
either an ACEI, an ARB, or both, after the onset of
their nephropathy. Statin therapy was begun if the low-
density lipoprotein (LDL) cholesterol was >100 mg/dL.
Furosemide was used as needed for edema control, blood
pressure control, or both. Diuretic therapy was generally
reduced as nephrotic proteinuria subsided. Dietary ther-
apy consisted of counseling to achieve a daily protein
intake of approximately 0.8 g/kg ideal body weight + 1 g
of dietary protein for each gram of proteinuria/24 hr, Na
intake of <120 mEq/day, and avoidance of excessive fluid
intake (>2.0 L/day) [16]. Two patients received chronic
warfarin therapy because of previous venous thrombosis.
Data analysis
Mean values are shown ± SD. The statistical tests used
are shown in relationship to the data. The definitions
used in our analysis include: nephrotic-range proteinuria,
urine protein (P)/creatinine (C) ratio ≥3.0; complete re-
mission, urine P/C ratio <0.5 (upper limits of normal for
urine P/C ratio = 0.25 in the study laboratory, The Ohio
State University Clinical Laboratories) partial remission,
50% or greater reduction of nephrotic-range proteinuria
and to a urine P/C ratio <3.0. The minimal duration of
remission was the 2-month period between consecutive
follow-ups. In almost all instances, the urine P/C ratios
were calculated from measurements made on samples
submitted as 24-hour collections. This should be more
accurate than spot urine P/C ratio to estimate 24-hour
proteinuria rate, and adjusts for differences in body size
among study participants [16].
RESULTS
Table 1 shows the individual patient baseline charac-
teristics. Our cohort is typical of SLE MN patients previ-
ously described [24]. Their age tended to be less than
35 years, 10/13 had nephrotic-range proteinuria, 11/13
were female, and elevated serum creatinine level oc-
curred in a minority of the patients. Mean study follow-up
was 16 ± 8 months.
Table 2 shows details of individual therapy. All patients
remain on MMF except patient 3. She participated in the
Ginzler study, where she received MMF 3000 mg daily
for 6 months, at which time it was stopped. The current
median MMF therapy is 1500 mg/day. Initial prednisone
therapy was 60 mg daily in patients 5 and 11 to treat asso-
ciated SLE enteritis. In most patients the prednisone dose
was tapered at the rate of 10 mg each 2 to 4 weeks. Dur-
ing follow-up, patients 1, 2, 3, and 5 each experienced a
minor extrarenal flare that required a temporary increase
in prednisone therapy. Patient 2 also experienced a mod-
erate renal flare (increase in urine P/C ratio from <0.5 to
1.8), which has resolved with increased therapy.
With respect to renoprotective/antiproteinuric thera-
pies, Table 3 shows that the blood pressure goal was
achieved in 10/13 patients. Each received an ACEI, ARB,
or both. Statins were used in 10/13 patients. All received
low-dose aspirin therapy. Most patients were compliant
with the goals of avoiding a high salt, protein, and fluid
intake [25], as shown in Table 2.
Figure 1 shows the changes in proteinuria in each of the
study patients since the start of MMF therapy. All but pa-
tient 8 showed reductions in proteinuria. By 6 months of
therapy, 10 of 13 experienced complete (N = 8) or partial
(N = 2) remission. By the most recent follow-up, 11 of
13 have achieved complete (N = 9) or partial remission
(N = 2) (Table 3). Patient 8 has not shown improvement
in proteinuria; however, she has been inconsistently com-
pliant with her treatment regimen. The others have been
consistently compliant.
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Table 1. Baseline characteristics of the study patients
Scrc C3/C4e WHO
Patient Age years Sex Racea BMIb mg/dL Urine P/Cd mg/dL aDS-DNAf UAg Class
1 43 M C 22.5 1.1 4.5 79/18 + >20/>5/5 V
2 23 F C 23.0 2.0 7.4 40/6 + 8/4/0 V
3 23 F A 42.6 0.7 4.0 189/44 − 1/0/0 V
4 22 F A 50.2 1.1 9.6 67/11 + >20/>5/6 V
5 26 F A 30.4 1.6 16.5 67/17 + 1/0/0 V
6 28 F C 33.9 1.2 3.4 73/15 − 20/5/2 V
7 49 F C 42.0 1.1 1.0 81/13 − 1/0/0 V
8 24 F A 27.4 0.8 4.4 58/14 + 2/0/1 V
9 21 F C 37.3 0.77 4.3 76/6 − 4/0/0 V+III
10 60 F C 27.8 0.6 1.7 142/20 − 1/0/3 V
11 51 F O 16.1 0.67 2.0 44/3 − 2/0/0 V
12 37 F C 25.8 0.68 4.2 53/7 + 0/0/0 V
13 20 M A 23.8 1.0 4.0 69/8 + 0/0/0 V
Mean ± SD 33 ± 14 31.0 ± 9.72 1.02 ± 0.41 5.1 ± 4.1 80 ± 41/14 ± 10
aC, Caucasian; A, African American; O, Oriental.
bBody mass index (weight, kg/height, m2).
cSerum creatinine.
dUrine protein/creatinine ratio based on 24-hour urine collection.
eComplement level C3, normal ≥80 mg/dL; C4, normal ≥12 mg/dL.
fAnti–double-stranded DNA antibody; +, present; −, absent.
gRed cells per high-power field/acanthocytes per high-power field/cellular casts (WBC or RBC casts per slide).
Table 2. Therapy of the study patients
MMFa mg/day Prednisone mg/day Blood pressurec 24-hour urined
Patient Initial Current Initial Current Other Rxb Systolic Diastolic Na mEq/day Urea g/day Volume mL/day
1 250 1500 40 10 As, R, S 126 ± 10 82 ± 6 127 ± 43 9.7 ± 1.5 1883 ± 405
2 1000 2000 20 15 A,As,B,D 118 ± 13 78 ± 8 154 ± 58 8.3 ± 2.5 972 ± 318
3 3000 0 10 5 A,As,D,S 133 ± 17 81 ± 12 130 ± 53 5.4 ± 2.5 1181 ± 306
4 2000 2000 20 10 D,R,W 119 ± 20 72 ± 11 145 3.0 1036
5 1000 1000 60 25 A,As,C,D,R,S 133 ± 17 95 ± 11 136 ± 79 6.5 ± 4.2 1021 ± 728
6 1000 1500 40 0 A,As,D,S 106 ± 23 72 ± 9 171 ± 49 6.8 ± 1.2 1904 ± 444
7 1000 1000 20 10 A,As,D,S 116 ± 10 81 ± 3 170 ± 34 13.8 ± 3.0 2126 ± 392
8 1000 1500 15 20 A,As 132 ± 22 81 ± 8 – – –
9 1000 500 40 15 A,As,S,W 125 ± 4 83 ± 4 388 ± 86 12.3 ± 8.5 2014 ± 386
10 500 500 10 6 A,As,S, 129 ± 8.5 74 ± 4 113 ± 36 7.1 ± 1.2 1471 ± 272
11 1000 1000 60 15 A,As,S 113 ± 1.4 77 ± 1 122 ± 33 6.6 ± 1.5 1936 ± 32
12 2000 2000 40 15 A,As,S 112 68 154 11.4 2480
13 500 2000 30 10 A,As,S 118 ± 5 71 ± 6 102 ± 23 7.0 ± 1.2 825 ± 272
Mean ± SD 1173 ± 746 1269 ± 665 31± 17 12 ± 7 122 ± 8 78 ± 7 159 ± 75 8.2 ± 3 1571 ± 551
aInitial, MMF dose 2 months after start of MMF; current, MMF dose at manuscript submission.
bOther therapy during follow-up: A, ACE inhibitor; As, aspirin 81 mg daily; D, diuretic; C, dihydropyridine calcium channel blocker; D, diuretic; R, angiotensin
receptor blocker; S, statin; W, warfarin.
cMean of the blood pressure measured at each 2-month visit.
dMean of the values measured generally each 2 months during follow-up; patient 4 submitted one 24-hour urine collection; patient 8 consistently submitted urine
collections that were less than 24-hour collection (e.g., 8- to 12-hour collections). Her values are not shown.
In no instance was it necessary to decrease MMF be-
cause of leukopenia, thrombocytopenia, or anemia. Pa-
tient 10 had mild diarrhea on MMF 750 mg twice daily.
The diarrhea cleared by decreasing MMF to 500 mg twice
daily.
The only serious complication was that patient 9 de-
veloped histoplasmosis pneumonia, requiring intubation
and ventilatory support. She may have been exposed
to histoplasmosis on her college campus where she en-
countered an excavation site daily and Canadian goose
droppings. She recovered completely, but remains on
long-term itraconazole therapy.
DISCUSSION
The present study shows that therapy with MMF, pred-
nisone, and renoprotective/antiproteinuria agents was as-
sociated with relatively rapid and marked proteinuria
reduction in 11/13 of our study cohort. Although sponta-
neous remission of nephrotic-range proteinuria is seen in
SLE MN, it occurs in a minority of patients, and generally
occurs over years of follow-up [11, 12], not within months
of the onset of therapy, as observed in our cohort. Thus,
we suggest that the relatively prompt improvement uni-
formly seen in our patients was the result of their therapy,
not spontaneous remission.
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Table 3. Current clinical status of each study patienta
Blood pressure
Follow-up
Patient Systolic Diastolic SCr Urine P/C C3 C4 a′DS-DNA UA #of months
1 124 82 0.9 0.088 64 13 – 0/0/0 30
2 122 82 0.9 0.426 90 12 – 2/1/0 28
3 138 84 0.8 0.668 144 27 – 1/0/0 20
4 108 70 0.7 0.068 171 26 + 3/2/0 18
5 136 92 1.6 3.585 73 16 – 0/0/0 18
6 100 60 0.8 0.200 85 20 – 3/0/0 18
7 130 82 1.0 0.426 126 20 – 0/0/0 14
8 146 94 1.1 5.150 30 8 + 2/1/1 12
9 128 86 0.8 0.638 108 20 – 3/1/1 12
10 126 72 0.8 0.188 124 19 – 0/0/0 6
11 112 78 0.7 0.307 70 9 – >20/0/0 4
12 112 68 0.6 0.381 93 11 – 0/0/0 6
13 118 62 1.02 0.162 96 14 – 2/1/0 24
Mean ± SD 123 ± 13 78 ± 1 0.90 ± 0.25 0.95 ± 1.56 98 ± 37 17 ± 6 16.15 ± 8.22


























Fig. 1. Sequential changes in urine protein/creatinine ratio in the study
cohort during study follow-up.
The extent to which our cohort’s improvement is at-
tributable to MMF, the other therapies they received, or
the combination, is not clear. However, it seems unlikely
that prednisone alone played a major role in the rapid
proteinuria reduction. As discussed earlier in the paper,
steroids alone are relatively ineffective in inducing and
sustaining remission of SLE MN nephrotic syndrome [11,
12].
Our patients’ antiproteinuria therapies likely con-
tributed to proteinuria reduction; however, it seems un-
likely that these therapies alone were responsible for the
observed marked proteinuria reductions. Consistent with
this interpretation are the previous studies of antiprotein-
uria therapy, showing that generally, proteinuria reduc-
tions of about 50% can be expected [16]. Also relevant
is the placebo-controlled trial of ACEI therapy in IgA
nephritis, an immune complex disease similar to SLE GN
[26]. In the Praga study, ACEI therapy was effective in re-
ducing proteinuria, but it did so slowly and only partially















Fig. 2. Kaplan-Meier estimates of the probability of a complete re-
mission or the composite of a complete or partial remission during
follow-up in the study.
In light of the above, it seems likely that steroid and
antiproteinuria therapy together cannot totally account
for the improvement in our patients. Therefore, we postu-
late that MMF therapy, through its immunosuppressive
and renoprotective effects [15], played a major role in
achieving the marked proteinuria reductions. The me-
dian MMF dose in our cohort (1500 mg/day) is less than
the MMF goal dose in the Ginzler study (3000 mg/day)
[abstract; Ginzler, Arth Rheum 48(Suppl):S647,]. Never-
theless, most of our patients have achieved suppression of
proteinuria, as well as SLE immunologic and inflamma-
tory phenomena based on the serial changes in C3, C4,
anti–double-stranded DNA antibodies, and urine sedi-
ment. Also, our patients’ complete or partial remission
rate at 6 months of therapy (10 of 13) compares favor-
ably with that of the Ginzler study (7 of 10 patients).
Miller et al [27] reported reduction in proteinuria in
only 50% of their patients with idiopathic MN, treated
with MMF for at least 6 months. Also, Kapitsinou et al
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[28] recently reported results less successful than ours
with the use of MMF in patients with SLE nephropa-
thy. Their results, which show less favorable response to
MMF, might be explained by their patients having pre-
viously failed other immunosuppressive therapies. Thus,
prior therapy should be taken into account in the design
of future trials of MMF therapy in SLE MN.
With regard to the duration of MMF therapy, our ex-
pectation is that treatment with MMF would not be in-
definite, but rather follow our SLE nephritis protocol,
which is to maintain therapy for 12 months beyond the
induction of complete remission, then taper the therapy.
CONCLUSION
The results of the Ginzler study and ours suggest that
MMF is effective therapy in SLE MN. Our study suggests
further that when MMF is combined with renoprotec-
tive/antiproteinuria therapies, moderate dose MMF ther-
apy is sufficient. A large-scale trial of MMF therapy in
SLE MN to test this hypothesis is warranted.
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